Malignant pleural mesothelioma (MPM) is a hard to treat malignancy arising from the mesothelial
surface of the pleura. Immune checkpoint inhibitors are considered a promising therapeutic strategy in many hardto-
treat malignancies. In this review, we are trying to provide an in depth coverage of the prognostic value of
immune checkpoints aberrations as well as discuss the different novel therapeutic strategies implementing these
agents in the management of MPM.
Keywords: Mesothelioma, tremelimumab, ipilimumab, pembrolizumab, immune, prognostic value.
Rights & PermissionsPrintExport